Syschol 500: Advanced Neuroprotective Support for Brain Health
Syschol 500 is a specialized neuroprotective medication containing 500mg of Citicoline (as Citicoline Sodium) per tablet. Manufactured by Micro Labs Limited, a reputable WHO-GMP certified pharmaceutical company, it is designed to support the brain's natural recovery processes and maintain cognitive function.
How Syschol 500 Works
The active ingredient, Citicoline, is a naturally occurring compound that serves as an intermediate in the synthesis of structural phospholipids in neuronal membranes, specifically phosphatidylcholine. By helping to maintain the integrity of brain cells, Syschol 500 supports efficient communication between neurons. It also promotes the production of acetylcholine, a critical neurotransmitter responsible for memory, focus, and overall cognitive performance.
Key Benefits and Uses in Nigeria
Syschol 500 is commonly recommended for several neurological and cognitive conditions under medical supervision:
- Stroke Recovery: It is often used to support neurological repair and minimize tissue damage following an ischemic stroke.
- Cognitive Support: Aids in managing cognitive decline and memory loss associated with neurodegenerative conditions.
- Head Injury Rehabilitation: Supports the brain's healing process after traumatic brain injuries (TBI).
- Glaucoma Support: Research suggests it may help protect optic nerve cells in some cases of glaucoma.
Dosage and Administration
Syschol 500 is available as film-coated tablets. The standard dosage is typically 500mg to 1000mg daily, but this must be determined by a healthcare professional based on the specific condition. It is classified as a Prescription Only Medicine (POM) in Nigeria.
Important Note: Citicoline tablets are sensitive to humidity. Always keep tablets in their original Alu-Alu blister packaging until ready for use to ensure stability.
For personalized guidance on dosage or to learn more about how Syschol 500 can support your recovery, you can contact a GoMed pharmacist online.